Veracyte, Inc.
VCYT
Positions held
Your positionsVCYT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Veracyte operates in a growing diagnostics market, which is increasingly focused on precision medicine and early disease detection, positioning the company for long-term growth.
- Revenue increased by 8% compared to the prior quarter, reaching $150 million.
- The company maintains a strong gross margin of 72.2%, indicating effective cost management.
- Veracyte has a high debt-to-equity ratio of 2.889, which may pose risks in a rising interest rate environment.
- The operating margin decreased from 16.3% to 15.3% in the latest quarter, indicating potential operational challenges.
- In 2023, the company reported a negative operating margin of -4.8%, reflecting financial instability during that year.
Fundamentals
| Market cap | $3.51B | Enterprise value | $3.06B | Trailing P/E | 31.14 | Forward P/E | 22.36 |
| PEG | — | Price / book | 2.52 | Beta | 1.95 | Dividend yield | 0.00% |
| Revenue growth | 15.5% | Earnings growth | — | Gross margin | 73.8% | Operating margin | 15.3% |
| Profit margin | 20.4% | ROE | 8.8% | ROA | 4.1% | Debt / equity | 0.03 |
| Current ratio | 9.16 | Free cash flow | $106.23M | Analyst recommendation | buy | Mean target | $58.42 |
| 52w high | $60.91 | 52w low | $29.46 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $150M | $139M | $141M | $132M | $130M | — |
| Op margin | 15.3% | 16.3% | 28.4% | 17.5% | 11.7% | — |
| Net income | $25.5M | $28.7M | $41.1M | $19.1M | -$1.0M | — |
| Gross margin | 72.2% | 72.7% | 72.5% | 69.2% | 69.0% | — |
| Gross profit | $109M | $101M | $102M | $91.3M | $89.8M | — |
| Operating income | $23.0M | $22.6M | $39.9M | $23.1M | $15.2M | — |
- Revenue +8% vs prior quarter ($150M vs $139M).
- Gross margin 72.2% (was 72.7% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $517M | $446M | $361M | $297M | — |
| Op margin | 15.1% | 4.4% | -4.8% | -11.9% | — |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M | — |
| Gross margin | 70.1% | 66.9% | 63.6% | 59.2% | — |
| Gross profit | $363M | $298M | $230M | $176M | — |
| Operating income | $78.3M | $19.5M | -$17.4M | -$35.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues
2026-10-08 · Is it the Right Time to Add Phibro Stock to Your Portfolio?
2026-10-08 · Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
2026-10-08 · Bruker Gains 66.3% in a Year: What's Driving the Rally?
2026-10-07 · Reasons to Hold HealthEquity Stock in Your Portfolio for Now
2026-10-07 · Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
2026-10-07 · Charles River Gains 75.8% in a Year: What's Driving the Rally?
2026-10-07 · Reasons to Add Globus Medical Stock to Your Portfolio Now
2026-10-07 · Is This the Right Time to Add TMO Stock to Your Portfolio?
2026-10-06 · Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
2026-10-06 · Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-05 · Cathie Wood Reworks Major Nvidia-AMD Position
Price (daily)
Full chart · RSI · MACD · patterns